Logo image of KRYS

KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis

USA - NASDAQ:KRYS - US5011471027 - Common Stock

192.16 USD
-3.8 (-1.94%)
Last: 10/21/2025, 11:31:10 AM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 534 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. A decent growth rate in combination with a cheap valuation! Better keep an eye on KRYS. These ratings could make KRYS a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

KRYS had positive earnings in the past year.
In the past year KRYS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
In the past 5 years KRYS reported 4 times negative operating cash flow.
KRYS Yearly Net Income VS EBIT VS OCF VS FCFKRYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of 12.89%, KRYS belongs to the best of the industry, outperforming 94.94% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.10%, KRYS belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
KRYS's Return On Invested Capital of 12.87% is amongst the best of the industry. KRYS outperforms 95.32% of its industry peers.
Industry RankSector Rank
ROA 12.89%
ROE 14.1%
ROIC 12.87%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
KRYS Yearly ROA, ROE, ROICKRYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

KRYS has a Profit Margin of 40.85%. This is amongst the best in the industry. KRYS outperforms 98.13% of its industry peers.
KRYS has a better Operating Margin (42.26%) than 98.88% of its industry peers.
KRYS's Gross Margin of 93.37% is amongst the best of the industry. KRYS outperforms 92.88% of its industry peers.
Industry RankSector Rank
OM 42.26%
PM (TTM) 40.85%
GM 93.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRYS Yearly Profit, Operating, Gross MarginsKRYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KRYS is creating some value.
Compared to 1 year ago, KRYS has more shares outstanding
The number of shares outstanding for KRYS has been increased compared to 5 years ago.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRYS Yearly Shares OutstandingKRYS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KRYS Yearly Total Debt VS Total AssetsKRYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

KRYS has an Altman-Z score of 36.23. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 36.23, KRYS belongs to the top of the industry, outperforming 94.94% of the companies in the same industry.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 36.23
ROIC/WACC1.37
WACC9.37%
KRYS Yearly LT Debt VS Equity VS FCFKRYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 9.68 indicates that KRYS has no problem at all paying its short term obligations.
KRYS has a Current ratio of 9.68. This is amongst the best in the industry. KRYS outperforms 80.52% of its industry peers.
KRYS has a Quick Ratio of 9.33. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.33, KRYS is in the better half of the industry, outperforming 79.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.68
Quick Ratio 9.33
KRYS Yearly Current Assets VS Current LiabilitesKRYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 2794.12% over the past year.
The Revenue has grown by 116.08% in the past year. This is a very strong growth!
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%

3.2 Future

Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 60.52% on average per year.
The Revenue is expected to grow by 32.95% on average over the next years. This is a very strong growth
EPS Next Y70.26%
EPS Next 2Y61.86%
EPS Next 3Y54.61%
EPS Next 5Y60.52%
Revenue Next Year32.01%
Revenue Next 2Y39.7%
Revenue Next 3Y41.08%
Revenue Next 5Y32.95%

3.3 Evolution

KRYS Yearly Revenue VS EstimatesKRYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KRYS Yearly EPS VS EstimatesKRYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 39.06, which means the current valuation is very expensive for KRYS.
KRYS's Price/Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 92.51% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.69, KRYS is valued a bit more expensive.
KRYS is valuated rather expensively with a Price/Forward Earnings ratio of 24.53.
KRYS's Price/Forward Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 91.57% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, KRYS is valued at the same level.
Industry RankSector Rank
PE 39.06
Fwd PE 24.53
KRYS Price Earnings VS Forward Price EarningsKRYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

92.88% of the companies in the same industry are more expensive than KRYS, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 94.19% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 29.99
EV/EBITDA 29.71
KRYS Per share dataKRYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

KRYS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
KRYS's earnings are expected to grow with 54.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y61.86%
EPS Next 3Y54.61%

More info and screens

0

5. Dividend

5.1 Amount

KRYS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KRYSTAL BIOTECH INC

NASDAQ:KRYS (10/21/2025, 11:31:10 AM)

192.16

-3.8 (-1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners95.05%
Inst Owner Change0.12%
Ins Owners11.86%
Ins Owner Change-1.19%
Market Cap5.56B
Analysts84.44
Price Target209.94 (9.25%)
Short Float %14.53%
Short Ratio9.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.87%
Min EPS beat(2)-13.89%
Max EPS beat(2)12.14%
EPS beat(4)2
Avg EPS beat(4)6.3%
Min EPS beat(4)-13.89%
Max EPS beat(4)27.68%
EPS beat(8)3
Avg EPS beat(8)-4.07%
EPS beat(12)5
Avg EPS beat(12)-8.82%
EPS beat(16)7
Avg EPS beat(16)-7.79%
Revenue beat(2)1
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-10.17%
Max Revenue beat(2)2.42%
Revenue beat(4)1
Avg Revenue beat(4)-2.48%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.42%
Revenue beat(8)4
Avg Revenue beat(8)8.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.05%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)-17.84%
EPS NY rev (1m)0.57%
EPS NY rev (3m)-11.52%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)-9.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.03%
Valuation
Industry RankSector Rank
PE 39.06
Fwd PE 24.53
P/S 15.48
P/FCF 29.99
P/OCF 28.46
P/B 5.34
P/tB 5.34
EV/EBITDA 29.71
EPS(TTM)4.92
EY2.56%
EPS(NY)7.83
Fwd EY4.08%
FCF(TTM)6.41
FCFY3.33%
OCF(TTM)6.75
OCFY3.51%
SpS12.41
BVpS35.96
TBVpS35.96
PEG (NY)0.56
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.89%
ROE 14.1%
ROCE 14.44%
ROIC 12.87%
ROICexc 36.62%
ROICexgc 36.62%
OM 42.26%
PM (TTM) 40.85%
GM 93.37%
FCFM 51.63%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 195.35%
Cap/Sales 2.77%
Interest Coverage 250
Cash Conversion 124.54%
Profit Quality 126.39%
Current Ratio 9.68
Quick Ratio 9.33
Altman-Z 36.23
F-Score8
WACC9.37%
ROIC/WACC1.37
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
EPS Next Y70.26%
EPS Next 2Y61.86%
EPS Next 3Y54.61%
EPS Next 5Y60.52%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%
Revenue Next Year32.01%
Revenue Next 2Y39.7%
Revenue Next 3Y41.08%
Revenue Next 5Y32.95%
EBIT growth 1Y3666.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y242.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y290.87%
OCF growth 3YN/A
OCF growth 5YN/A